Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Shizuo Kasai

Asato Kina

Takeshi Yamasaki

Tohru Yamashita

Hideki Hirose

Tsuyoshi Maekawa

Nobuyuki Takakura

Hideki Furukawa

Minoru Yoshida

Jumpei Aida

Hideyuki Igawa

Masahiro Kamaura

Koji Watanabe

Tomohiro Kaku

Yasufumi Miyamoto

Toshitake Kobayashi

Yasuhiro Hirata

Seiji Miwatashi

Yoichi Nishikawa

Yuko Hitomi

Yayoi Nakayama

Naoyoshi Noguchi

Satoshi Sasaki

Norihito Tokunaga

Kazuaki Takami

Tomohiro Okawa

Masaki Ogino

Shigemitsu Matsumoto

Keiko Kakegawa

Akito Shibuya

Yoshito Terao

Nobuo Cho

Ryo Mizojiri

Kousuke Hidaka

Mrinalkanti Kundu

Sachie Morimoto

Masashi Takahashi

Ryoma Hara

Uttam Khamrai

Takashi Nakahata

Kevin Francis McGee, Jr

Jr Kevin Francis Mcgee

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for&#x2014;diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like. 

IP6K inhibitors

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: 

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification. 

Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

Aromatic ring compound

The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.

Heterocyclic compound

Benzimidazole derivatives as MCH receptor antagonists

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein,or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.

The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, which has a superior RBP4-lowering action and is useful as a pharmaceutical composition for the prophylaxis or treatment of a disease or condition mediated by an increase in RBP4. 

Derivatives of N-acyl-N'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes

The present invention relates to a compound represented by wherein each symbol is as defined in the specification, a salt thereof and the like.

Growing community of inventors

Kanagawa, Japan

Shizuo Kasai